Yasuo Kodama

Medicine · Health Sciences

13h-index592citations74works5.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacological Effects and Toxicity Studies(25), Heat shock proteins research(15), Epilepsy research and treatment(13), Drug Transport and Resistance Mechanisms(13), HIV/AIDS drug development and treatment(12)

Publications74 total

Correction to “Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)”
Journal of Medicinal Chemistry·2025
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
Journal of Medicinal Chemistry·2024· 10 citedOpen Access
Supplementary Figure S1 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Data from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Supplementary Table S3 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Supplementary Table S3 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Supplementary Table S1 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Data from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Supplementary Table S2 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Supplementary Table S2 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Supplementary Figure S1 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Supplementary Table S1 from TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
2023Open Access
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use
ACS Medicinal Chemistry Letters·2023· 31 citedOpen Access
Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors
Journal of Medicinal Chemistry·2021· 17 citedOpen Access
Abstract 1039: Fragment-based drug discovery to identify small molecule allosteric inhibitors of SHP2
Cancer Research·2020
Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor
Journal of Medicinal Chemistry·2018· 55 citedOpen Access
Abstract 4784: TAS0286/HM05, a novel highly selective RET inhibitor, prominently inhibits various RET defective tumor growth
Cancer Research·2018· 1 cited
Survey of Pharmacists' Views on Rx-to-OTC Switched Drugs
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)·2017· 1 citedOpen Access
Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan
Drugs in R&D·2016· 1 citedOpen Access
Evaluation of Safety Profiles of Blood Cancer Drugs Approved in Japan
Therapeutic Innovation & Regulatory Science·2015· 1 cited
page 1 of 4Next →

Frequent Co-authors

Shunsuke Ono(16), Hirofumi Kodama(14), Masae Kuranari(13), Masaharu Takeyama(11), Isao Fujii(9), Akio Fujimura(8), Kazuyuki Saito(8), Hiromi Muraoka(6), Chihoko Yoshimura(6), Makoto Kitade(6), Kimiko Tsutsumi(6), Yoshihiro Shibata(5), Shinya Shinozawa(5), Reizo Kanemaru(5), Kazunari Todaka(5), Yoshio Mitsuyama(5), Shuichi Ohkubo(4), Kenjiro Ito(4), Kazuhiko Yonekura(4), Satoshi Yamashita(4)